Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks

Surinder S Birring; Peter V Dicpinigaitis; Jaclyn A Smith; Alyn H Morice; Lorcan P McGarvey; Ian D Pavord; Allison Martin Nguyen; Jonathan Schelfhout; Qing Li; Beata Iskold; Stuart A Green; George Philip; David R Muccino; Carmen La Rosa

doi:10.1164/rccm.202211-2128LE

Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks

Surinder S Birring, Peter V Dicpinigaitis, Jaclyn A Smith, Alyn H Morice, Lorcan P McGarvey, Ian D Pavord, Allison Martin Nguyen, Jonathan Schelfhout, Qing Li, Beata Iskold, Stuart A Green, George Philip, David R Muccino, Carmen La Rosa

Division of Immunology, Immunity to Infection and Respiratory Medicine

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	1539-1542
Number of pages	4
Journal	American Journal of Respiratory and Critical Care Medicine
Volume	207
Issue number	11
DOIs	https://doi.org/10.1164/rccm.202211-2128LE
Publication status	Published - 1 Jun 2023

Keywords

Humans
Cough/drug therapy
Antitussive Agents/adverse effects
Pyrimidines/therapeutic use
Sulfonamides/therapeutic use
Chronic Disease

Access to Document

10.1164/rccm.202211-2128LELicence: CC BY-NC-ND

Cite this

Birring, S. S., Dicpinigaitis, P. V., Smith, J. A., Morice, A. H., McGarvey, L. P., Pavord, I. D., Nguyen, A. M., Schelfhout, J., Li, Q., Iskold, B., Green, S. A., Philip, G., Muccino, D. R., & La Rosa, C. (2023). Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks. American Journal of Respiratory and Critical Care Medicine , 207(11), 1539-1542. https://doi.org/10.1164/rccm.202211-2128LE

@article{d81818da0d8d4e49a7c52fd21255edd6,

title = "Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks",

keywords = "Humans, Cough/drug therapy, Antitussive Agents/adverse effects, Pyrimidines/therapeutic use, Sulfonamides/therapeutic use, Chronic Disease",

author = "Birring, {Surinder S} and Dicpinigaitis, {Peter V} and Smith, {Jaclyn A} and Morice, {Alyn H} and McGarvey, {Lorcan P} and Pavord, {Ian D} and Nguyen, {Allison Martin} and Jonathan Schelfhout and Qing Li and Beata Iskold and Green, {Stuart A} and George Philip and Muccino, {David R} and {La Rosa}, Carmen",

year = "2023",

month = jun,

day = "1",

doi = "10.1164/rccm.202211-2128LE",

language = "English",

volume = "207",

pages = "1539--1542",

journal = "American Journal of Respiratory and Critical Care Medicine ",

issn = "1073-449X",

publisher = "American Thoracic Society",

number = "11",

}

Birring, SS, Dicpinigaitis, PV, Smith, JA, Morice, AH, McGarvey, LP, Pavord, ID, Nguyen, AM, Schelfhout, J, Li, Q, Iskold, B, Green, SA, Philip, G, Muccino, DR & La Rosa, C 2023, 'Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks', American Journal of Respiratory and Critical Care Medicine , vol. 207, no. 11, pp. 1539-1542. https://doi.org/10.1164/rccm.202211-2128LE

TY - JOUR

T1 - Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks

AU - Birring, Surinder S

AU - Dicpinigaitis, Peter V

AU - Smith, Jaclyn A

AU - Morice, Alyn H

AU - McGarvey, Lorcan P

AU - Pavord, Ian D

AU - Nguyen, Allison Martin

AU - Schelfhout, Jonathan

AU - Li, Qing

AU - Iskold, Beata

AU - Green, Stuart A

AU - Philip, George

AU - Muccino, David R

AU - La Rosa, Carmen

PY - 2023/6/1

Y1 - 2023/6/1

KW - Humans

KW - Cough/drug therapy

KW - Antitussive Agents/adverse effects

KW - Pyrimidines/therapeutic use

KW - Sulfonamides/therapeutic use

KW - Chronic Disease

UR - http://www.scopus.com/inward/record.url?scp=85160969396&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/efdd617c-5900-33fe-beba-6eaafee8ebbe/

U2 - 10.1164/rccm.202211-2128LE

DO - 10.1164/rccm.202211-2128LE

M3 - Letter

C2 - 36996347

SN - 1073-449X

VL - 207

SP - 1539

EP - 1542

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

IS - 11

ER -

Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks

Keywords

Access to Document

Other files and links

Cite this